DGX

Quest Diagnostics stock has experienced notable events in the past six months. As of May 7, 2026, the stock was up 8.08% over the past 12 months, with a 52-week range between $164.65 and $213.50, closing at $190.84 on May 7, 2026. The company priced a $500 million senior notes issue. Analysts have upgraded their outlook for DGX amid strong first-quarter growth, and the company reported strong Q1 2026 financial results, leading to raised revenue and EPS guidance for the full year 2026. In Q1 2026, Quest Diagnostics saw a 9.2% year-over-year revenue increase and a 13% EPS growth, with total requisition volume increasing by 10.9%.